Researchers offer new targets for drugs against fatty liver disease and liver cancer

Researchers offer new targets for drugs against fatty liver disease and liver cancer
Co‐expression networks were generated for 46 tissues that had more than 50 samples from GTEx RNA‐seq data. In each tissue, researchers found groups of highly co‐expressed genes, called co‐expression clusters, by using a community detection algorithm. Among these groups, they selected key co‐expression clusters on the basis of their clustering coefficients. Credit: KTH Royal Institute of Technology

There may no silver bullet for treating liver cancer or fatty liver disease, but knowing the right targets will help scientists develop the most effective treatments. Researchers in Sweden have just identified a number of drug targets that can be used in the development of efficient new treatment strategies with minimal side effects.

Researchers from KTH Royal Institute of Technology's Science for Life Laboratory (SciLifeLab) research center and Gothenburg University employed the biological networks generated for 46 major human tissues in order to identify the liver-specific gene targets. The results were published in Molecular Systems Biology, an EMBO Press Journal.

The researchers mapped the metabolic changes caused by accumulated fat in , and combined this data with an analysis of biological networks of liver and other human tissues. Doing so enabled them to identify the liver-specific drug targets whose inhibition will not cause any side effect to other human tissues, says lead author Adil Mardinoglu, a SciLifeLab fellow, who had earlier established a connection between NAFLD and HCC and increased fat synthesis in .

Hepatic steatosis is the excessive accumulation of fat in the liver and it is the key characteristic of non-alcoholic (NAFLD). It is one of the most common chronic liver problems in the world, and affects almost 30 percent of the adult population. The disease is the consequence of obesity, diabetes, or excessive alcohol intake and can lead to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatic failure. There are few treatments, even though the need is urgent.

Mardinoglu says the team's network modeling approach, which relied on data from the Sweden-based Human Protein Atlas project and The Genotype-Tissue Expression (GTEx) project consortia, can be used in the identification of drug targets, and eventually in the development of efficient strategies for treating a number of .

To validate their computer modeling predictions, the researchers performed experiments in human cancer cell lines, mouse liver samples and primary human hepatocytes. They validated their predictions by demonstrating functional relationships between these liver gene, and showed that their inhibition decreases cell growth and liver fat content, Mardinoglu says. The researchers identified liver-specific genes linked to NAFLD pathogenesis, such as pyruvate kinase liver and red blood cell, (PKLR), or to HCC pathogenesis, such as PKLR, patatin-like phospholipase domain containing 3 (PNPLA3) and proprotein convertase subtilisin/kexin type 9 (PCSK9), all of which are potential targets for drug development.

Mathias Uhlen, director of the Human Protein Atlas project and co-author of the paper, says, "I am extremely pleased that the resource created through the Human Protein Atlas effort has been used in the analysis of clinical data obtained from liver disease patients and that this analysis has led to the identification of -specific that can be used for treatment of this clinically important patient group."


Explore further

New treatment for fatty liver disease and type 2 diabetes burns up fat in liver

More information: "Network analyses identify liver‐specific targets for treating liver diseases" Molecular Systems Biology (2017) 13, 938, DOI: 10.15252/msb.20177703
Journal information: Molecular Systems Biology

Citation: Researchers offer new targets for drugs against fatty liver disease and liver cancer (2017, August 22) retrieved 23 August 2019 from https://medicalxpress.com/news/2017-08-drugs-fatty-liver-disease-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
9 shares

Feedback to editors

User comments

Sep 14, 2017
Drugs are identified by the body and if they are xenobiotic (most pharmaceutical drugs), it must be broken down by the liver. This additional strain is why there aren't any successful drugs for fatty liver in the market. You must increase glutathione conjugation, sulphation and methylation to promote phase 2 detox in the liver. Hepatiben from Liver Medic does just that while also addressing disrepair in the gut lining. Drugs are not the answer in this case. Good health to you.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more